Applied Molecular Transport Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Applied Molecular Transport is gedaald met een gemiddeld jaarlijks tempo van -25.6%, terwijl de winst van de sector Biotechs jaarlijks groeide met 19.3%.

Belangrijke informatie

-25.6%

Groei van de winst

13.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-460.5%
Nettomarge	n/a
Laatste winstupdate	30 Sep 2023

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Here's Why We're A Bit Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Mar 07

We're A Little Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Nov 13

Applied Molecular Transport GAAP EPS of -$0.93

Aug 04

Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky

Jul 27

Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data

Jul 05

Applied Molecular: Interesting Drug Delivery Approach For The GI Tract

May 03

We're Keeping An Eye On Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Apr 28

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Jan 08

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Aug 29

Applied Molecular Transport (NASDAQ:AMTI) Is In A Good Position To Deliver On Growth Plans

Apr 05

Have Insiders Been Buying Applied Molecular Transport Inc. (NASDAQ:AMTI) Shares This Year?

Feb 11

Here's Why We're Not Too Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Dec 21

Applied Molecular Transport reports Q3 results

Nov 12

Opbrengsten en kosten

Hoe Applied Molecular Transport geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqCM:AMTI Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 23	-75	29	-11
30 Jun 23	-93	30	7
31 Mar 23	-112	32	27
31 Dec 22	-126	37	45
30 Sep 22	-134	37	64
30 Jun 22	-135	37	64
31 Mar 22	-122	35	58
31 Dec 21	-100	29	41
30 Sep 21	-89	25	58
30 Jun 21	-80	20	27
31 Mar 21	-72	16	23
31 Dec 20	-67	13	54
30 Sep 20	-55	10	30
30 Jun 20	-46	7	46
31 Mar 20	-38	6	33
31 Dec 19	-28	4	24

Kwaliteitswinsten: AMTI is momenteel verliesgevend.

Groeiende winstmarge: AMTI is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: AMTI is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 25.6% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van AMTI over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: AMTI is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: AMTI heeft een negatief Return on Equity ( -460.5% ), omdat het momenteel verliesgevend is.

Applied Molecular Transport Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Applied Molecular Transport Files Form 15

Applied Molecular Transport Inc.(NasdaqCM:AMTI) dropped from NASDAQ Composite Index

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

New minor risk - Shareholder dilution

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

New major risk - Market cap size

Applied Molecular Receives Letter from Nasdaq Regarding Listing Rule 5100

New major risk - Revenue and earnings growth

New major risk - Market cap size

Applied Molecular Transport Inc. Announces Executive Changes

Price target decreased by 39% to US$0.90

Here's Why We're A Bit Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Applied Molecular Transport Receives Non-Compliance Notice From Nasdaq

Applied Molecular Transport Inc. Announces Resignation of Randall Mrsny from the Board of Directors

Applied Molecular Transport Inc. Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

Independent Director recently bought US$150k worth of stock

Price target increased to US$13.67

We're A Little Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Applied Molecular Transport Completes Enrollment of Phase 2 Lombard Monotherapy Trial of Oral Amt-101 in Patients with Moderate-To-Severe Ulcerative Colitis

Forecast to breakeven in 2024

Applied Molecular Transport GAAP EPS of -$0.93

Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky

Applied Molecular Transport Announces Top-Line Phase 2 Results from Market Combination Trial of Oral AMT-101 in Patients with Moderate-To-Severe Ulcerative Colitis

Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data

Applied Molecular Transport Inc.(NasdaqGS:AMTI) dropped from Russell 2000 Growth Index

Independent Director recently bought US$211k worth of stock

Insider recently bought US$306k worth of stock

Price target decreased to US$54.08

Applied Molecular: Interesting Drug Delivery Approach For The GI Tract

We're Keeping An Eye On Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Applied Molecular Transport to Report Top-Line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

Price target decreased to US$58.28

Applied Molecular Transport Inc., Annual General Meeting, May 24, 2022

Applied Molecular Transport Inc. Appoints Charlene Banard to Its Board of Directors

Price target decreased to US$69.00

Independent Director recently bought US$318k worth of stock

Less than half of directors are independent

Applied Molecular Transport Inc. Announces Management Changes

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Chief Medical Officer exercised options to buy US$458k worth of stock.

Co-Founder recently bought US$52k worth of stock

Insider recently bought US$250k worth of stock

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Chief Financial Officer exercised options and sold US$255k worth of stock

Chief Business & Strategy Officer exercised options and sold US$289k worth of stock

Independent Chairman recently sold US$8.7m worth of stock

Applied Molecular Transport Inc.(NasdaqGS:AMTI) dropped from Russell 2500 Value Index

Chief Medical Officer exercised options and sold US$393k worth of stock

Applied Molecular Transport (NASDAQ:AMTI) Is In A Good Position To Deliver On Growth Plans

Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126

New 90-day high: US$64.47

Applied Molecular Transport Inc. Enter into a Lease Agreement with Are-East Jamie Court, LLC

Have Insiders Been Buying Applied Molecular Transport Inc. (NASDAQ:AMTI) Shares This Year?

New 90-day high: US$39.85

Applied Molecular Transport Inc. Appoints Douglas Rich as Chief Technical Officer

New 90-day high: US$34.38

Here's Why We're Not Too Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Applied Molecular Transport reports Q3 results

Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of Novel Oral Il-10 Biologic Therapeutic (Amt-101) for Inflammatory Diseases in the Journal of Immunology

New 90-day high: US$35.00

New 90-day high - US$31.11

Applied Molecular Transport Inc. announced that it has received $32.999975 million in funding

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden